Effect of cavity absorption on treatment outcomes of Mycobacterium kansasii pulmonary disease

被引:0
|
作者
Zou, Xin [1 ,3 ,5 ]
Yi, Shulin [2 ]
Luo, Mengxing [1 ,3 ]
Zeng, Qibing [3 ]
Yao, Shixiu [4 ]
Chen, Lulu [1 ,3 ]
Yao, Xin [1 ,3 ]
Hu, Yang [1 ]
Liu, Zhonghua [1 ,3 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai Key Lab TB, Shanghai, Peoples R China
[2] Yingtan Peoples Hosp, Dept Resp & Crit Care Med, Yingtan, Peoples R China
[3] Guizhou Med Univ, Sch Publ Hlth, Key Lab Environm Pollut Monitoring & Dis Control, Minist Educ, Guiyang, Peoples R China
[4] Shanghai Jiao Tong Univ, Xinhua Hosp, Clin Res & Innovat Ctr, Sch Med, Shanghai, Peoples R China
[5] Yibin Ctr Dis Control & Prevent, Hlth Surveillance Sect, Yibin 644600, Sichuan, Peoples R China
关键词
Absorption of pulmonary cavities; Effect of treatment; Mycobacterium kansasii; Treatment outcome; CLINICAL-FEATURES; NONTUBERCULOUS MYCOBACTERIA; INFECTION; TUBERCULOSIS;
D O I
10.1016/j.diagmicrobio.2025.116712
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The incidence of Mycobacterium kansasii pulmonary disease (MK-PD) was increasing worldwide. However, limited research was conducted on how to improve the cure rate and evaluate treatment efficacy for patients. We aimed to identify key factors that could improve the cure rate in patients with MK-PD. Methods: In this retrospective cohort study, the medical records of patients with MK-PD, registered with Shanghai Pulmonary Hospital between January 2016 and December 2020, were collected. These included data on demographics, as well as clinical, radiological, microbiological, drug resistance, and drug regimen information, and treatment outcomes. Multivariate logistic regression analysis was conducted to identify risk factors for treatment failure in patients. Results: This study included 129 patients, of whom 100 (77.5 %) were treated successfully. Logistic regression analysis identified non-absorption of pulmonary cavities as an independent risk factor for treatment successful (odds ratio: 7.9, 95 %confidence interval: 1.7-36.2, p = 0.008). The overall cure rate for patients with absorption of pulmonary cavities (APC) was 93 %; 55 % of patients began resorption within 6 months of the start of treatment (the cure rate was 95 %). The APC rate of patients with MK-PD negatively correlated with the number of comorbidities (p = 0.009); that was, the more comorbidities, the more difficult the cavity absorption and the lower the cure rate. Conclusions: The absorption of pulmonary cavities was the key to the cure rate for patients with MK-PD. Early changes in cavities helped identify the effect of treatment and guide doctors in optimizing treatment plans to improve patient cure rates.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Hypercalcaemia in Mycobacterium kansasii pulmonary infection
    Flowers, Robert Costigan
    Ocampo, Javier
    Krautbauer, Justin
    Kupin, Warren L.
    BMJ CASE REPORTS, 2021, 14 (11)
  • [22] Treatment alternatives for Mycobacterium kansasii
    Graybill, JR
    Bocanegra, R
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (04) : 417 - 420
  • [23] Clofazimine for the Treatment of Mycobacterium kansasii
    Srivastava, Shashikant
    Gumbo, Tawanda
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (08)
  • [24] PULMONARY DISEASE DUE TO RIFAMPIN-RESISTANT MYCOBACTERIUM KANSASII IN AN ADOLESCENT
    Polat, Meltem
    Parlakay, Aslinur Ozkaya
    Tapisiz, Anil
    Cakmak, Pinar
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2020, 56 (03) : 489 - 489
  • [25] Pulmonary Mycobacterium kansasii infection: Comparison of the clinical features, treatment and outcome with pulmonary tuberculosis
    Evans, SA
    Colville, A
    Evans, AJ
    Crisp, AJ
    Johnston, IDA
    THORAX, 1996, 51 (12) : 1248 - 1252
  • [26] TREATMENT OF PULMONARY-DISEASE DUE TO MYCOBACTERIUM-KANSASII - RECENT EXPERIENCE WITH REGIMENS CONTAINING RIFAMPIN
    PEZZIA, W
    RALEIGH, JW
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1974, 109 (06): : 716 - 716
  • [27] Treatment of pulmonary disease caused by Mycobacterium kansasii: Results of 18 vs 12 months' chemotherapy - Reply
    Sauret, J
    TUBERCLE AND LUNG DISEASE, 1995, 76 (06): : 583 - 583
  • [28] The clinical characteristics of Mycobacterium fortuitum pulmonary disease and the treatment outcomes
    Kim, Sae Rom
    Jhun, Byung Woo
    RESPIROLOGY, 2023, 28 : 124 - 124
  • [29] Clinical Characteristics and Treatment Outcomes of Mycobacterium fortuitum Pulmonary Disease
    Kim, Sae Rom
    Yu, Jin Young
    Kim, Su-Young
    Kim, Dae Hun
    Jhun, Byung Woo
    MICROBIOLOGY SPECTRUM, 2023, 11 (04):
  • [30] Outcomes of Surgical Treatment for Mycobacterium abscessus Complex Pulmonary Disease
    Togo, Takeo
    Atsumi, Jun
    Hiramatsu, Miyako
    Shimoda, Kiyomi
    Morimoto, Kozo
    Shiraishi, Yuji
    ANNALS OF THORACIC SURGERY, 2022, 113 (03): : 949 - 956